Keywords
interactions
efficacy
safety
How to Cite
Abstract
The goal is to analyze the interactions between antiretroviral drugs and other medications prescribed for patients with HIV and identify pharmaceutical risks, analysing the influence they have on viral load and other types of treatments, and thus ensuring their efficacy and safety, all in collaboration with the doctor.
Material and methods: it is a retrospective study conducted in April- May 2021, including all the patients attended by a doctor and a pharmacist in the outpatient infectious diseases clinic. Data were collected using electronic clinical record: age, gender, viral load, antiretroviral treatment, and other treatments. Patients have been divided into different groups according to the third antiretroviral treatment drug. Interactions, the interaction level, and the influence of antiretrovirals on blood concentration have also been collected.
Results: 100 patients have been analysed. The median age is 52 (P25: 36; P75: 59); 72 % are male. The 95 % have less than 50 copies/ml. As third drug, 33 patients have an integrase inhibitor, 26 a non-nucleoside reverse transcriptase inhibitor, 23 the potentiated protease inhibitor and 17 other combinations. Of all patients, 68 are taking medicines other than HIV. In total, there are 229 drugs, 3.3 drugs per patient. Of these 229 drugs, 57 (24.9 %) had some interaction: 39 (68.4 %) are very relevant, 17 (29.8 %) not relevant and 1 (1.8 %) is contraindicated. Some therapeutic groups had higher prevalence of interactions.
Conclusion: 24.9 % of drugs have interactions, of which 68.4 % are very relevant. Validation by a pharmacist improves the detection of interactions and therefore ensures safety.
References
CDC: Acerca del VIH [Internet]. [Leku zehaztugabea]: Centros para el Control y Prevención de Enfermedades; 2022ko irailaren 7an eguneratua [Kontsulta: 2022-04-15]. Eskuragarri: https://www.cdc.gov/hiv/spanish/basics/whatishiv.html
Osasun Eskola: GIB/HIESA [Internet]. Vitoria-Gateiz: Osakidetza; Eusko Jaurlari-tzako Osasun Saila; 2022ko ekainaren 10ean eguneratua [Kontsulta: 2022-04-15]. Eskuragarri: https://www.osakidetza.euskadi.eus/hiesa/
Hiesa eta Sexu Transmisiozko Infekzioen Plana-Memoria 2020 = Plan del Sida Transmisión Sexual e Infecciones de 2020 [Internet]. Vitoria-Gasteiz: Osakidetza, Eusko Jaurlaritzako Osasun Saila; 2020 [Kontsulta: 2022-04-16]. Eskuragarri: https://www.osakidetza.euskadi.eus/contenidos/informacion/osk_osaesk_salud_sex_vih/es_def/adjuntos/ Memoria_VIH_2020_v2.pdf
GESIDA: Documento de Consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodefi-ciendia humana [Internet]. [Madrid]: Grupo de Estudio del SIDA-SEIMC; 2020 [Kontsulta: 2022-04-16]. 23 or. Eskuragarri: https://gesida-seimc.org/wp- con-tent/uploads/2020/07/TAR_GUIA_GESIDA_2020_COMPLETA_Julio.pdf
Lexicomp® Drug Interactions. Hemen: UpToDate®[Internet]. Watham (MA): Upto-date; [Kontsulta: 2021-04 eta 2021-05]. Eskuragarri: https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist
HIV Drug interactions [Internet]. Liverpool: University of Liverpool; 2022ko urria-ren 12an eguneratua [Kontsulta: 2021-04 eta 2021-05]. Eskuragarri: https://www.hiv- druginteractions.org/checker.
Micromedex: Drugs Interactions [Internet]. IBM Micromedex Solutions; [Kontsul-ta: 2021-04 eta 2021-05]. Eskuragarri: https://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deepLink&SearchT erm=drug%20interactions
Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en paci-entes ambulatorios con tratamiento anti-retroviral [Internet]. Revista chilena de infectología. 2012 Abu [Kontsulta: 2022-05-05];29(4):412-416. Eskuragarri: http://dx.doi.org/10.4067/S0716-10182012000400008
López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan Á, McAllister K, Bellón J, Gibbons S, Balsalobre P, Pérez-Latorre L, Benedí J, Marzolini C, Aranguren-Oyarzábal A, Khoo S, Calvo-Alcántara M, Berenguer J. Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a popu-lation-based study [Internet]. Clinical Infectious Diseases. 2019 Abu 20 [Kontsulta: 2022-05-10];71(2):353-362. Eskuragarri: https://doi.org/10.1093/cid/ciz811
Demessine L, Payro-Saint-Paul L, Gardner E, Ghosn J, Parienti J-J. Risk and cost associated with drug-drug interactions among aging HIV patients receiving com-bined antiretroviral therapy in France [Internet]. Open Forum Infecious Diseases. 2019 Mar 22 [Kontsulta: 2022-05-15];6(3):ofz051. Eskuragarri: https://doi.org/10.1093/ofid/ofz051
Manzardo C, Tuset M, Miróa JM, Gatell JM. Interacciones graves o potencialmen-te letales entre antirretrovirales y otros medicamentos. Enfermedades Infeccio-sas y Microbiología Clínica. 2015;33(7):e15-e30.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Ber-nasconi E, Khoo S, Battegay M, Elzi L, Böni J, Bucher H-C, Bürgisser P, Cattacin S, Dubs R, Egger M, Fischer M, Flepp M, Fontana A, Francioli P, Furrer H, Fux C, Gorgievski M, Günthard H, Hirsch H-H, Hirschel B, Hösli I, Kahler C, Kaiser L, Ka-rrer U, Kind C, Klimkait T, Ledergerber B, Martinetti G, Martinez B, Müller N, Na-dal D, Opravil M, Paccaud F, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schmid P, Schultze D, Schüpbach J, Speck R, Taffé P, Tarr P, Telenti A, Trkola A, Yerly S. Ageing with HIV: medication use and risk for potential drug–drug interactions [Internet]. Journal of Antimicrobial Chemotherapy. 2011 Ira [Kontsulta: 2022-09- 08];66(9):2107-2111. Eskuragarri: https://doi.org/10.1093/jac/dkr248
Molas E, Luque S, Retamero A, Echeverría-Esnal D, Guelar A, Montero M, Guerri R, Sorli L, Lerma E, Villar J, Knobel H. Frequency and severity of potential drug in-teractions in a cohort of HIV-infected patients Identified through a Multidiscipli-nary team [Internet]. HIV Clinical Trials. 2018 [Kontsulta: 2022-09-08];19(1):1-7. Eskuragarri: https://www.tandfonline.com/doi/full/10.1080/15284336.2017.1404690
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Osagaiz: osasun-zientzien aldizkaria